RxDoctor Payments Data

Mark Fisch, MD

Interventional Cardiology · Indianapolis, INNPI 1346448305

Payments from drug & device makers

$1,571in general payments, 2019–2025

Across 77 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$280
  • Boston Scientific$261
  • Amgen$236
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$99
  • Novartis$70
  • Shockwave Medical, Inc$68
  • plus $558 from 16 others

What the payments were for

  • Food & beverage$1,571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,571 in reported general payments places this provider in the 15th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$209,491
Medicare patients
1,982
Services billed
3,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban606$700,242
EntrestoSacubitril/Valsartan201$192,824
XareltoRivaroxaban124$125,635
Repatha SureclickEvolocumab95$93,558
BrilintaTicagrelor58$51,966
Praluent PenAlirocumab53$29,241
FarxigaDapagliflozin Propanediol16$19,408
Ezetimibe379$13,410
JardianceEmpagliflozin15$11,597
Metoprolol Succinate697$9,252
Atorvastatin Calcium786$9,210
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,720
Losartan Potassium465$5,962
Rosuvastatin Calcium361$5,727
Carvedilol596$5,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$700,242606 claims
NovartisEntresto$70$192,824201 claims
AstraZenecaBrilinta, Farxiga$21$71,37474 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →